Thermo Fisher Scientific (NYSE:TMO) VP Lisa Britt Sells 5,850 Shares of Stock

Thermo Fisher Scientific Inc. (NYSE:TMO) VP Lisa Britt sold 5,850 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $580.00, for a total value of $3,393,000.00. Following the sale, the vice president directly owned 14,784 shares in the company, valued at $8,574,720. This trade represents a 28.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Thermo Fisher Scientific Price Performance

Shares of TMO stock traded up $13.09 on Friday, reaching $593.11. The company’s stock had a trading volume of 2,206,647 shares, compared to its average volume of 2,321,357. The stock’s fifty day simple moving average is $515.61 and its 200-day simple moving average is $510.03. Thermo Fisher Scientific Inc. has a 1 year low of $435.27 and a 1 year high of $643.99. The company has a market capitalization of $219.30 billion, a price-to-earnings ratio of 31.90, a price-to-earnings-growth ratio of 2.35 and a beta of 0.85. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. During the same quarter in the prior year, the firm earned $4.28 earnings per share. Thermo Fisher Scientific’s revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be issued a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.11%.

Analysts Set New Price Targets

TMO has been the topic of a number of recent research reports. KeyCorp restated an “overweight” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. Stifel Nicolaus set a $650.00 target price on Thermo Fisher Scientific in a research report on Wednesday. Royal Bank Of Canada raised their price target on Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a “sector perform” rating in a research report on Friday, July 24th. Barclays boosted their price objective on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an “overweight” rating in a research report on Friday, July 24th. Finally, Weiss Ratings raised shares of Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, July 14th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $619.41.

Institutional Investors Weigh In On Thermo Fisher Scientific

Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its position in Thermo Fisher Scientific by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company’s stock valued at $19,778,774,000 after acquiring an additional 288,296 shares during the last quarter. J. Stern & Co. LLP lifted its position in shares of Thermo Fisher Scientific by 58,006.4% during the fourth quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock worth $18,258,082,000 after purchasing an additional 31,455,105 shares during the last quarter. BlackRock Inc. purchased a new stake in shares of Thermo Fisher Scientific during the second quarter valued at $15,501,867,000. State Street Corp grew its holdings in shares of Thermo Fisher Scientific by 1.4% in the fourth quarter. State Street Corp now owns 16,613,761 shares of the medical research company’s stock worth $9,633,991,000 after purchasing an additional 229,630 shares during the last quarter. Finally, Capital World Investors increased its stake in Thermo Fisher Scientific by 7.0% in the 4th quarter. Capital World Investors now owns 11,003,814 shares of the medical research company’s stock worth $6,376,229,000 after buying an additional 718,669 shares during the period. 89.23% of the stock is owned by institutional investors.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.